Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Anticoagulation

Warfarin use linked to increased risk of knee and hip replacement

Research presented at the American College of Rheumatology’s annual meeting finds that use of warfarin can increase the risk of needing knee or hip replacement surgery.

warfarin

Source: Shutterstock.com

The risk of knee or hip replacement surgery was found to increase with duration of warfarin use

Use of warfarin, a vitamin K antagonist, is associated with a significantly greater risk of knee and hip replacements compared with use of direct oral anticoagulants (DOACs), according to research presented at the American College of Rheumatology’s annual meeting on 7 November 2020[1].

The team identified 913 patients who had either had a knee or hip replacement (as an indicator of end-stage osteoarthritis) and matched them with 3,652 controls. Of the 913 surgery cases, 64.9% were warfarin users and 35.1% were DOAC users.

After adjusting for potential confounders, the researchers found that warfarin users had 1.57 times higher odds of having a knee or hip replacement than DOAC users (adjusted odds ratio 1.57, 95% confidence interval 1.30–1.89).

The risk of knee or hip replacement surgery was found to increase with duration of warfarin use.

“Our research supports the importance of adequate vitamin K and dependent proteins for limiting progression of [osteoarthritis],” said Priyanka Ballal, a rheumatology fellow at Boston University and lead author of the study.

“Given these potential adverse effects of warfarin on joint health, our study suggests that direct oral anticoagulants could be considered for managing atrial fibrillation among patients who have [osteoarthritis].”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2020.20208634

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Patient Care in Community Practice

    Patient Care in Community Practice

    Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.

    £22.00Buy now
  • Clinical Pharmacokinetics

    Clinical Pharmacokinetics

    A practical guide to the use of pharmacokinetic principles in clinical practice. Includes case studies with questions and answers.

    £33.00Buy now
  • Strategic Medicines Management

    Strategic Medicines Management

    A practical guide to influencing the availability of medicines, and policies of their use. Focuses on the strategic elements of medicines management.

    £33.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.